✨ Free AI Report
Artelo Biosciences, Inc.: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research Artelo Biosciences, Inc.
Company Research

Artelo Biosciences, Inc.: Business Overview, Financials & Competitive Analysis

Artelo Biosciences is a clinical stage biopharmaceutical company that develops and commercializes therapeutics targeting lipid-signaling pathways in the United States. The company is advancing a portfolio of broadly a...

Analyst-debate audio for Artelo Biosciences, Inc.

AskCyborg analysts argue the bull and bear cases for Artelo Biosciences, Inc. across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
4/ 10Weak

Cyborg Score thesis

High-risk clinical-stage play on endocannabinoid and lipid-signaling biology; execution risk outweighs pipeline optionality for...

Read the full analyst-debate transcript →
Industry Biotechnology
2 named competitors
2 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: September 21, 2026
AI-Verified Research
30+ Page Report

Get the Latest Artelo Biosciences, Inc. Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Artelo Biosciences, Inc. Overview

Pro stress-test →

Artelo Biosciences is a clinical stage biopharmaceutical company that develops and commercializes therapeutics targeting lipid-signaling pathways in the United States. The company is advancing a portfolio of broadly applicable product candidates designed to address significant unmet needs in multiple diseases and conditions, including anorexia, cancer, anxiety, dermatologic conditions, pain, and inflammation.

Strategic Profile

Pro stress-test →

Artelo's pipeline includes ART27.13 (synthetic dual cannabinoid agonist in Phase 1b/2a for cancer-related anorexia), ART12.11 (cannabidiol-tetramethylpyrazine cocrystal for anxiety, depression, PTSD, epilepsy, and insomnia), and ART26.12 (FABP5 inhibitor for neuropathy and cancer-related conditions). The company positions itself at the intersection of oncology supportive care and CNS conditions with lipid-pathway modulation as its scientific differentiator.

Competitive Landscape

Pro stress-test →

Artelo competes in clinical-stage cannabinoid-derived therapeutics and lipid-signaling modulators against companies pursuing similar endocannabinoid or fatty-acid pathway targets. Direct competitors are limited at early clinical stage, though the company faces broader competition from established oncology supportive care players and mood/anxiety developers. Clinical-stage biotech peers include companies with CBD/cannabinoid programs and FABP inhibitor platforms, though few are as advanced in human trials.

Industry Context

Artelo Biosciences, Inc. operates in Biotechnology.

Key facts

Founded: 2011 · Headquarters: Solana Beach, California, US · Revenue: Estimated $0 (pre-revenue clinical-stage)

What the analysts stress-tested

The top findings that survived the multi-agent debate for Artelo Biosciences, Inc..

  • Clinical-stage biopharmaceutical company focused on modulating lipid-signaling pathways across oncology, pain, dermatological, and neurological indications; core pipeline includes ART27.13 (Phase 1b/2a, cancer-related anorexia), ART26.12 (Phase 1, pain/neuropathy), and ART12.11 (anxiety/depression/PTSD).
  • Executed two reverse stock splits in 2026: 3-for-1 split (March 10, 2026) and 1-for-9 split (August 31, 2026), reflecting ongoing capital structure management and exchange listing compliance challenges typical of micro-cap biotech.
+2 more stress-tested counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

  • August 20261-for-9 reverse stock split announced
  • September-October 2025Public offering of 441,210 shares at $4.40/share; offering closed in October 2025
Get alerted when Artelo Biosciences, Inc. has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

Jazz PharmaceuticalsDiversified pharma with oncology and CNS focus→Alnylam PharmaceuticalsRNA interference therapeutics platform→

Compare Artelo Biosciences, Inc. with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

Artelo Biosciences, Inc. operates in Biotechnology. See how the rest of the sector scores on the Cyborg framework.

Top companies in Biotechnology by Cyborg Score

Browse Biotechnology research →
NEW · MCP server

Ask your AI assistant about Artelo Biosciences, Inc.

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare Artelo Biosciences, Inc. and its top competitor on Cyborg Score”
“What did Artelo Biosciences, Inc. do this quarter?”
“Is Artelo Biosciences, Inc. a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg builds confidence

⚔

Analyst debate, not single-author opinion

Every report is stress-tested by a panel of AI analysts arguing across 11 dimensions. The output is the part of the case that survived pushback.

📊

Recalibrated weekly

The Cyborg Score is recomputed weekly against fresh data. Recent material developments are continuously tracked and surfaced.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The same company gets the same score from any analyst running the framework.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, news flow, and proprietary analyst signals. Read the methodology →

Frequently asked questions

What does Artelo Biosciences, Inc. do?+
Artelo Biosciences is a clinical stage biopharmaceutical company that develops and commercializes therapeutics targeting lipid-signaling pathways in the United States. The company is advancing a portfolio of broadly a...
What is Artelo Biosciences, Inc.'s Cyborg Score?+
Artelo Biosciences, Inc. has a Cyborg Score of 4/10 (Weak). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are Artelo Biosciences, Inc.'s main competitors?+
Named competitors include Jazz Pharmaceuticals, Alnylam Pharmaceuticals. The full competitive landscape is in the AskCyborg report.
How can I get the full Artelo Biosciences, Inc. research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the Artelo Biosciences, Inc. research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track Artelo Biosciences, Inc. over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

More Biotechnology research

Companies in the same sector and named competitors, ranked by Cyborg Score.

8Abivax SA8Bavarian Nordic A/S8Beam Therapeutics Inc.8CG Oncology, Inc.8Cogent Biosciences, Inc.8COMPASS Pathways plc8CSL Limited8Eckert & Ziegler SE8Krystal Biotech, Inc.8Legend BiotechTop companies in Biotechnology by Cyborg Score